Roche will expand its cancer monitoring footprint through an acquisition of MRD testing technology from SAGA Diagnostics, with Foundation Medicine set to integrate the platform. The deal is valued at up to $595 million including milestone payments and is expected to close by the third quarter of 2026, subject to regulatory approvals. Foundation Medicine will bring in SAGA’s Pathlight MRD platform, which uses whole genome sequencing and digital PCR to detect and track structural variants with ultra-sensitive precision. The company said Pathlight is already covered by Medicare for monitoring recurrence in early-stage breast cancer, and it is available in the US with plans to expand internationally. Foundation Medicine also outlined a roadmap for collaboration with Roche to pursue a more decentralized MRD offering using Roche AXELIOS sequencing and Digital LightCycler PCR platforms.